FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3030203629> ?p ?o ?g. }

• W3030203629 endingPage "91" @default.
• W3030203629 startingPage "83" @default.
• W3030203629 abstract "Evidence on long-term effectiveness and cost effectiveness of treatment sequences for multiple myeloma (MM) is sparse. We used published data and country-specific data to assess the cost effectiveness of four-line treatment sequences for elderly transplant-ineligible patients with MM in Serbia.We developed a Markov cohort model to compare long-term effectiveness and cost effectiveness of five sequential MM treatment alternatives from the perspective of the national healthcare provider. Effectiveness parameters on progression, mortality and adverse events were extracted from published clinical trials. Costs were based on price lists of the National Health Insurance Fund. We compared life expectancy, costs, and incremental cost-effectiveness ratios among alternative courses of action. The model was analyzed over a lifelong time horizon applying a 3% annual discount rate for effectiveness outcomes and costs. Robustness of the model was tested in multiple deterministic sensitivity analyses.The sequences were defined by the frontline treatment: MPT (melphalan-prednisone-thalidomide), MPV (melphalanprednisone-bortezomib), CTD (cyclophosphamide-thalidomide-dexamethasone), VCD (bortezomib-cyclophosphamidedexamethasone) and BP (bendamustine-prednisone). MPV sequence resulted in the highest remaining life expectancy (4.76 life years). Cost-effectiveness analysis resulted in three non-dominated strategies: MPT, VCD, and MPV sequences, with an incremental cost-effectiveness ratio of EUR 35,300 per life-year gained (LYG) for VCD and EUR 47,200/LYG for MPV relative to MPT.MPV sequence was the most effective in terms of life expectancy for elderly transplant-ineligible MM patients in Serbia. Bortezomib-based strategies would be recommended for the frontline treatment of patients with MM in Serbia if the willingness-to-pay threshold is around EUR 35,000-60,000/LYG.O dolgoročni uspešnosti in stroškovni učinkovitosti zaporedij zdravljenja multiplega mieloma (MM) ni veliko dokazov. Na podlagi objavljenih podatkov in podatkov za posamezne države smo ocenili stroškovno učinkovitost štirih zaporedij zdravljenja starejših bolnikov z MM, ki niso primerni za presaditev, v Srbiji.Za primerjanje dolgoročne uspešnosti in stroškovne učinkovitosti petih alternativ zaporednega zdravljenja MM z vidika nacionalnega izvajalca zdravstvenega varstva smo razvili kohortni model Markova. Parametre uspešnosti glede napredovanja, umrljivosti in neželenih dogodkov smo pridobili iz objavljenih kliničnih preskušanj. Stroški temeljijo na cenikih nacionalnega sklada za zdravstveno zavarovanje. Med različnimi ukrepi smo primerjali pričakovano življenjsko dobo, stroške in mejno razmerje stroškovne učinkovitosti. Model smo analizirali v vseživljenjskem časovnem okviru, pri čemer smo za rezultate uspešnosti in stroške uporabili 3-odstotno letno diskontno stopnjo. Robustnost modela smo preizkusili z več determinističnimi analizami občutljivosti.Zaporedja so bila opredeljena z zdravljenjem v prvi liniji: MPT (melfalan-prednizon-talidomid), MPV (melfalanprednizon-bortezomib), CTD (ciklofosfamid-talidomid-deksametazon), VCD (bortezomib-ciklofosfamid-deksametazon) in BP (bendamustin-prednizon). Pri zaporedju MPV je bila pričakovana preostala življenjska doba najdaljša (4,76 leta življenja). Pri analizi stroškovne učinkovitosti so bile ugotovljene tri neprevladujoče strategije: zaporedja MPT, VCD in MPV z mejnim razmerjem stroškovne učinkovitosti 35.300 EUR na pridobljeno leto življenja (LYG) za VCD in 47.200 EUR/LYG za MPV glede na MPT.Zaporedje MPV je bilo najuspešnejše v smislu pričakovane življenjske dobe starejših bolnikov z MM, ki niso primerni za presaditev, v Srbiji. Strategije, ki temeljijo na bortezomibu, bi bile priporočljive za zdravljenje bolnikov z MM v prvi liniji v Srbiji, če je prag pripravljenosti na plačilo približno 35.000–60.000 EUR/LYG." @default.
• W3030203629 created "2020-06-05" @default.
• W3030203629 creator A5007269697 @default.
• W3030203629 creator A5018772359 @default.
• W3030203629 creator A5024148786 @default.
• W3030203629 creator A5026642457 @default.
• W3030203629 creator A5034696787 @default.
• W3030203629 creator A5045608423 @default.
• W3030203629 creator A5068420742 @default.
• W3030203629 creator A5070604720 @default.
• W3030203629 creator A5071272497 @default.
• W3030203629 creator A5090743122 @default.
• W3030203629 date "2020-04-06" @default.
• W3030203629 modified "2023-10-01" @default.
• W3030203629 title "Long-Term Effectiveness and Cost Effectiveness of Multiple Myeloma Treatment Strategies for Elderly Transplant-Ineligible Patients in Serbia" @default.
• W3030203629 cites W1531345979 @default.
• W3030203629 cites W1534666283 @default.
• W3030203629 cites W1724355557 @default.
• W3030203629 cites W1965428196 @default.
• W3030203629 cites W1983236139 @default.
• W3030203629 cites W1988265934 @default.
• W3030203629 cites W1991892404 @default.
• W3030203629 cites W1992979998 @default.
• W3030203629 cites W2018491765 @default.
• W3030203629 cites W2029867957 @default.
• W3030203629 cites W2039217634 @default.
• W3030203629 cites W2044636425 @default.
• W3030203629 cites W2073228314 @default.
• W3030203629 cites W2074264250 @default.
• W3030203629 cites W2074533771 @default.
• W3030203629 cites W2074734350 @default.
• W3030203629 cites W2076003266 @default.
• W3030203629 cites W2081866049 @default.
• W3030203629 cites W2082741854 @default.
• W3030203629 cites W2085092835 @default.
• W3030203629 cites W2096207943 @default.
• W3030203629 cites W2103289287 @default.
• W3030203629 cites W2104678903 @default.
• W3030203629 cites W2114217833 @default.
• W3030203629 cites W2114538178 @default.
• W3030203629 cites W2132708603 @default.
• W3030203629 cites W2134023402 @default.
• W3030203629 cites W2136561725 @default.
• W3030203629 cites W2146679542 @default.
• W3030203629 cites W2156082358 @default.
• W3030203629 cites W2156492908 @default.
• W3030203629 cites W2167468313 @default.
• W3030203629 cites W2254978625 @default.
• W3030203629 cites W2290002113 @default.
• W3030203629 cites W2346242965 @default.
• W3030203629 cites W2460673902 @default.
• W3030203629 cites W2480110608 @default.
• W3030203629 cites W2549396793 @default.
• W3030203629 cites W2803602511 @default.
• W3030203629 cites W2803679599 @default.
• W3030203629 cites W2885738414 @default.
• W3030203629 cites W2887448109 @default.
• W3030203629 cites W2959201308 @default.
• W3030203629 cites W3121501471 @default.
• W3030203629 doi "https://doi.org/10.2478/sjph-2020-0011" @default.
• W3030203629 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7478073" @default.
• W3030203629 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32952707" @default.
• W3030203629 hasPublicationYear "2020" @default.
• W3030203629 type Work @default.
• W3030203629 sameAs 3030203629 @default.
• W3030203629 citedByCount "0" @default.
• W3030203629 crossrefType "journal-article" @default.
• W3030203629 hasAuthorship W3030203629A5007269697 @default.
• W3030203629 hasAuthorship W3030203629A5018772359 @default.
• W3030203629 hasAuthorship W3030203629A5024148786 @default.
• W3030203629 hasAuthorship W3030203629A5026642457 @default.
• W3030203629 hasAuthorship W3030203629A5034696787 @default.
• W3030203629 hasAuthorship W3030203629A5045608423 @default.
• W3030203629 hasAuthorship W3030203629A5068420742 @default.
• W3030203629 hasAuthorship W3030203629A5070604720 @default.
• W3030203629 hasAuthorship W3030203629A5071272497 @default.
• W3030203629 hasAuthorship W3030203629A5090743122 @default.
• W3030203629 hasBestOaLocation W30302036291 @default.
• W3030203629 hasConcept C112930515 @default.
• W3030203629 hasConcept C126322002 @default.
• W3030203629 hasConcept C133925201 @default.
• W3030203629 hasConcept C143998085 @default.
• W3030203629 hasConcept C2776364478 @default.
• W3030203629 hasConcept C2777478702 @default.
• W3030203629 hasConcept C2779609412 @default.
• W3030203629 hasConcept C2779900020 @default.
• W3030203629 hasConcept C2908647359 @default.
• W3030203629 hasConcept C3019080777 @default.
• W3030203629 hasConcept C64332521 @default.
• W3030203629 hasConcept C71924100 @default.
• W3030203629 hasConcept C99454951 @default.
• W3030203629 hasConceptScore W3030203629C112930515 @default.
• W3030203629 hasConceptScore W3030203629C126322002 @default.
• W3030203629 hasConceptScore W3030203629C133925201 @default.
• W3030203629 hasConceptScore W3030203629C143998085 @default.
• W3030203629 hasConceptScore W3030203629C2776364478 @default.
• W3030203629 hasConceptScore W3030203629C2777478702 @default.
• W3030203629 hasConceptScore W3030203629C2779609412 @default.

• next